E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
OncoCyte's adjusted earnings per share data for the fiscal year that ended in Dec. 2021 was $-0.720. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Dec. 2021.
As of today (2023-02-06), OncoCyte's current stock price is $ 0.40265. OncoCyte's E10 for the fiscal year that ended in Dec. 2021 was $. OncoCyte's Shiller PE Ratio of today is .
OncoCyte E10 Historical Data
The historical data trend for OncoCyte's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
OncoCyte Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
E10
-
-
-
-
-
OncoCyte Quarterly Data
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
E10
-
-
-
-
-
Competitive Comparison
For the Biotechnology subindustry, OncoCyte's E10, along with its competitors' market caps and E10 data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoCyte E10 Distribution
For the Biotechnology industry and Healthcare sector, OncoCyte's E10 distribution charts can be found below:
* The bar in red indicates where OncoCyte's E10 falls in comparison to its industry or sector. The grey bar indicates the E10's extreme value range as defined by GuruFocus.
OncoCyte E10 Calculation
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, OncoCyte's adjusted earnings per share data for the fiscal year that ended in Dec. 2021 was:
OncoCyte does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate it.
OncoCyte (NAS:OCX) E10 Explanation
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Be Aware
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
OncoCyte E10 Related Terms
Thank you for viewing the detailed overview of OncoCyte's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.01(3.24%) Volume: 223,251 2:25PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
OCX has been successfully added to your 
